Neurocrine Biosciences (NBIX) Equity Ratio (2010 - 2026)

Neurocrine Biosciences has reported Equity Ratio for 17 years, with the latest figure at 0.69 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio rose 1.0% year-over-year to 0.69; the trailing twelve-month figure through Mar 2026 stood at 0.69 (up 1.0% YoY), and the FY2025 full-year result was 0.7, up 0.86% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.69, down from 0.7 in the prior quarter.
• The five-year high for Equity Ratio was 0.77 in Q3 2024, with the low at 0.65 in Q1 2022.
• Historically, Equity Ratio has averaged 0.71 across 5 years, with a median of 0.7 in 2023.
• Annual changes were most pronounced in 2023 — Equity Ratio climbed 10.04% — and 2025, when it fell 8.77%.
• Neurocrine Biosciences' Equity Ratio stood at 0.72 in 2022, then dropped by 4.79% to 0.69 in 2023, then grew by 1.45% to 0.7 in 2024, then rose by 0.86% to 0.7 in 2025, then fell by 1.12% to 0.69 in 2026.
• The last three Equity Ratio figures came in at 0.69 (Q1 2026), 0.7 (Q4 2025), and 0.7 (Q3 2025), per Business Quant data.